Physician profile
Daphne Robakis
NPI 1396075255
$2,919.16
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $418 · 2020: $186 · 2021: $1,770 · 2022: $386 · 2023: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $160.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $1,758.50 | 2019-2021 | |
| Abbott Laboratories | $275.15 | 2022 | |
| Merz North America, INC. | $136.61 | 2019-2020 | |
| Medtronic, INC. | $95.63 | 2022 | |
| Acadia Pharmaceuticals INC | $81.00 | 2023 | Nuplazid |
| Grifols USA, LLC | $71.06 | 2019-2020 | |
| Mdd US Operations, LLC | $69.19 | 2019-2021 | |
| Medtronic USA, INC. | $65.39 | 2019 | |
| Ucb, INC. | $60.68 | 2019-2021 | |
| Greenwich Biosciences, INC. | $51.90 | 2019 | |
| Alnylam Pharmaceuticals INC. | $37.55 | 2023 | Amvuttra |
| Catalyst Pharmaceuticals, INC. | $28.92 | 2021 | |
| Acorda Therapeutics, INC | $28.82 | 2019 | |
| Immedica Pharma US, INC. | $25.95 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $25.47 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $23.63 | 2019 | |
| Ge Healthcare | $20.68 | 2019 | |
| Lundbeck LLC | $18.36 | 2019 | |
| Abbvie INC. | $15.67 | 2023 | Duopa |
| Genentech USA, INC. | $14.89 | 2022 | |
| Akcea Therapeutics, INC. | $14.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daphne Robakis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.